IgG Antibodies to GlcNAcβ and Asialo-GM2 (GA2) Glycans as Potential Markers of Liver Damage in Chronic Hepatitis C and the Efficacy of Antiviral Treatment

Total serum IgG level is a surrogate marker of hepatitis C (HC) severity. Antibodies (Abs) to microbial glycans could be markers of HC severity caused by the translocation of microbial products. The level of anti-glycan (AG) Abs was analysed in serum samples of patients (n=128) with chronic HC in EL...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Disease markers 2018, Vol.2018 (2018), p.1-13
Hauptverfasser:	Kuznetsova, Tatiana, Kurtenkov, Oleg, Sergejev, Boris, Smorodin, Eugeniy, Geller, Julia
Format:	Artikel
Sprache:	eng
Schlagworte:	Adhesins Antibodies Antigens Bacterial infections Blood groups Clinical medicine Consent Damage assessment Enzyme-linked immunosorbent assay Fibrosis Genotypes Glycan Hepatitis Hepatitis C Immune response Immune system Immunoglobulin G Immunoglobulins Infections Interferon Liver Markers Microorganisms Parameter sensitivity Patients Phosphatase Polyethylene glycol Polysaccharides Sensitivity Sensitivity analysis Translocation
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Total serum IgG level is a surrogate marker of hepatitis C (HC) severity. Antibodies (Abs) to microbial glycans could be markers of HC severity caused by the translocation of microbial products. The level of anti-glycan (AG) Abs was analysed in serum samples of patients (n=128) with chronic HC in ELISA using fourteen synthetic glycans present in microbes and adhesins to evaluate the association of Abs with clinical parameters and the efficacy of antiviral treatment. The anti-GlcNAcβ IgG level was significantly higher in patients with fibrosis (P=0.021) and severe portal inflammation (P
ISSN:	0278-0240 1875-8630
DOI:	10.1155/2018/4639805